細(xì)胞名稱(chēng)

人彌漫性大B細(xì)胞淋巴瘤細(xì)胞DoHH2

貨物編碼

BFN60808592

產(chǎn)品規(guī)格

T25培養(yǎng)瓶x1

1.5ml凍存管x2

細(xì)胞數(shù)量

1x10^6

1x10^6

保存溫度

37℃

-198℃

運(yùn)輸方式

常溫保溫運(yùn)輸

干冰運(yùn)輸

安全等級(jí)

1

用途限制

僅供科研      3類(lèi)

培養(yǎng)體系

DMEM高糖培養(yǎng)基+10%FBS+1%三抗

培養(yǎng)溫度

37℃

二氧化碳濃度

5%

簡(jiǎn)介

人彌漫性大B細(xì)胞淋巴瘤細(xì)胞DoHH2取自60歲男性，該細(xì)胞源于DSMZ

注釋

Part of: Cancer Cell Line Encyclopedia (CCLE) project.

Part of: COSMIC cell lines project.

Part of: LL-100 blood cancer cell line panel.

Part of: MD Anderson Cell Lines Project.

Part of: TCGA-110-CL cell line panel.

Doubling time: 48 hours, in RPMI 1640 + 5% FBS (PubMed=1849602); ~40 hours (DSMZ).

Microsatellite instability: Stable (MSS) (Sanger).

Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).

Omics: Array-based CGH.

Omics: Deep exome analysis.

Omics: Deep RNAseq analysis.

Omics: DNA methylation analysis.

Omics: Genome sequenced.

Omics: H3K9ac ChIP-seq epigenome analysis.

Omics: Protein expression by reverse-phase protein arrays.

Omics: SNP array analysis.

Omics: Transcriptome analysis.

Omics: Virome analysis using RNAseq.

Miscellaneous: Originally assigned to be from a B-cell non-Hodgkin lymphoma, immunoblastic-type.

Derived from sampling site: Pleural effusion.

基因突變

HLA信息

Class I

HLA-A        A*01:01,01:01

HLA-B        B*08:01,44:02

HLA-C        C*07:04,07:04

Class II

HLA-DQ        DQA1*01:02,01:02

DQB1*05:01,06:02

HLA-DR        DRB1*15:01,01:01

STR信息

Amelogenin        X,Y

CSF1PO        11,12

D3S1358        15,17

D5S818        11,12

D7S820        11

D8S1179        13,16

D13S317        12,13

D16S539        11,14

D18S51        11,14

D21S11        30

FGA        21,27

Penta D        9,12

Penta E        12,16

TH01        9

TPOX        8,11

vWA        14,19

參考文獻(xiàn)

 PubMed=30285677; DOI=10.1186/s12885-018-4840-5

Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X., Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H., Koeffler H.P.

Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.

BMC Cancer 18:940-940(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747

Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)

PubMed=31160637; DOI=10.1038/s41598-019-44491-x

Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M., MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.

The LL-100 panel: 100 cell lines for blood cancer studies.

Sci. Rep. 9:8218-8218(2019)

PubMed=31395879; DOI=10.1038/s41467-019-11415-2

Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M., van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.

Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.

Nat. Commun. 10:3574-3574(2019)